中国免疫学杂志2024，Vol.40Issue(1)：152-155,162,5.DOI:10.3969/j.issn.1000-484X.2024.01.023
免疫治疗对RPL患者妊娠结局的影响及安全性研究
Effect and safety of immunotherapy on pregnancy outcome in patients with RPL
摘要
Abstract
Objective:To evaluate clinical efficacy and safety of immunotherapy by retrospectively analyzing clinical medica-tion of patients with recurrent pregnancy loss(RPL)complicated with abnormal immune factors.Methods:A retrospective cohort study was conducted on RPL cases in outpatient department of Hebei Reproductive Health Hospital from January 2021 to April 2022.Efficacy and safety of immunotherapy were evaluated from pregnancy outcome,adverse reactions and birth defects of offspring.Results:According to guidelines,192 cases with abnormal autoimmunity and/or immune indicators were included.Early abortion rate was 4.16%in group of two lost pregnancies,which was lower than that in group of three lost pregnancies(16.66%).Twelve week sus-tained pregnancy rate was 89.58%in the former group,and 28 week sustained pregnancy rate was 86.45%,which were significantly higher than those in the latter group(75.00%,71.87%).RPL patients were divided into groups according to their exposure to immuno-modulatory drugs before 12 weeks of pregnancy.There was no significant difference in pregnancy outcome,adverse reaction rate and birth defect rate of their offspring(P>0.05).Conclusion:Immunotherapy can effectively reduce risk of recurrent abortion and increase rate of persistent pregnancy in patients with immune RPL.Personalized immunotherapy can make RPL patients with immune factors achieve expected effect of fetal protection.关键词
反复妊娠丢失/免疫球蛋白/生物制剂/妊娠结局Key words
Repeated pregnancy loss/Immunoglobulin/Biological agents/Pregnancy outcome分类
医药卫生引用本文复制引用
茹慧波,董九华,吴纯,王琇,王树松,杜丽荣..免疫治疗对RPL患者妊娠结局的影响及安全性研究[J].中国免疫学杂志,2024,40(1):152-155,162,5.基金项目
河北省省级科技计划(223777151D,21377799D) （223777151D,21377799D）
河北省中医药类科研计划课题(2021205). （2021205）
